As in 2020, CRISPR still doesn't have an approved product -- but that could change soon. The stock has been volatile, providing investors with potential for both big gains and losses. But now that the ...

LabRoots invites you to the 3rd Annual Event in the CRISPR Virtual Event Series! This event will continue the conversation of the abilities of CRISPR-based editing, next-gen editing tools, precision ...

Genome editing technologies, such as CRISPR, are being applied to better understand basic biological systems as well as to research new kinds of gene and cell therapies. The CRISPR-Cas9 system ...

Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to appear soon after birth. To date, there haven’t been many reliable ...

How did this new software originate, and what does it do? Scientists and collaborators at the ChristianaCare Gene Editing Institute developed this tool to fill in the gaps in analysis that existed in ...

This week marks an incredible win for modern medicine. The first CRISPR-based gene therapy has just been approved for clinical use in the United Kingdom. Casegvy (Exa-cel), developed by Vertex and ...

Growth stocks took off during 2020 amid the early stages of the pandemic. Buying during that time led to significant profits for some investors. One of the stocks that benefited from that bullishness ...